Some users believe creatine may accelerate hair loss, while others see no effect. Opinions are mixed, with some suggesting using treatments like finasteride to counter potential effects.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
This user has conducted data scraping of 365 Reddit posts on the hairloss drug Pyrilutamide over the last year to analyse efficacy and side effects. The findings, which are available in a 19 page report with graphs, suggest that 22% of Pyrilutamide users experience positive results while 63% experience symptoms. A larger analytics project is proposed for other drugs with enough demand.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
PP405 is likely a scam, with concerns about its legitimacy and safety, as it may cause unintended tissue growth. Users suggest sticking to known treatments like finasteride and minoxidil.
Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
The conversation discusses hair loss and queries the effectiveness of treatments like PRP, Exosome therapy, peptides, and Stem Cell therapy. Specific treatments like Minoxidil, finasteride, and RU58841 are also mentioned.
P5P supplementation helped reverse finasteride side effects, particularly by lowering prolactin levels and restoring sensitivity. The user experienced significant improvement within a day and full recovery in a few days.
The user is seeking an alternative solvent for pyrilutamide due to skin irritation from ethanol and propylene glycol. They experienced similar issues with topical minoxidil.
The conversation discusses hair loss treatments, specifically PRP, Minoxidil, and Finasteride. The user is considering PRP but is concerned about its effectiveness and potential side effects, while another user suggests starting with Minoxidil and possibly adding Finasteride later.
Kintor is producing a cosmetic with KX826, starting at 0.5% concentration and moving to 1%. The 0.5% concentration wasn't as effective as minoxidil and finasteride, but the 1% concentration shows promise.
The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.
25-year-old male with Norwood 2 hair loss tried PRP injections without success. Dermatologists didn't recommend finasteride or minoxidil, but suggested PRP + Mesotherapy for 50% improvement.
A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.
The user is seeking advice on treating male pattern baldness (MPB) while dealing with seborrheic dermatitis, specifically asking about the use of finasteride (Fin) and minoxidil (Min). They are concerned about side effects and are looking for recommendations to improve overall hair thickness, especially on the crown.
Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
Exploring the potential of using Verteporfin to grow follicles in combination with microneedling, as well as the cost of administering a single injection and the possibility of combining it with minoxidil.
Users discuss using pyrilutamide for hair loss, seeking alternatives to 5AR inhibitors. They mention using minoxidil, ketoconazole shampoo, and RU58841.
PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.
PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.
A user shared their 14-month progress using Pyrilutamide and Minoxidil for hair loss, noting improvement and no side effects with these treatments, unlike their negative experiences with Finasteride and RU58841. They emphasized the importance of consistent application for seeing results.
PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.
PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.